Prosecution Insights
Last updated: August 18, 2026

Citius Pharmaceuticals Inc.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (67%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
33% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HEITMEIER, KENDALL NICOLE 1 63.9% +41.7%
LEE, ANDREW ELDRIDGE 1 17.0% +32.0%
BENAVIDES, JENNIFER ANN 1 51.3% +48.6%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17409589 METHODS OF TREATING CANCER BENAVIDES, JENNIFER ANN 23d
19412192 HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS HEITMEIER, KENDALL NICOLE
18648288 METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF LEE, ANDREW ELDRIDGE

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
17409589 METHODS OF TREATING CANCER BENAVIDES, JENNIFER ANN 23d
19412192 HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS HEITMEIER, KENDALL NICOLE
18648288 METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF LEE, ANDREW ELDRIDGE

Top Art Units

Art UnitApps
1621 1
3684 1
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19412192 HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS HEITMEIER, KENDALL NICOLE 1621 §101§103§112 Non-Final OA Pending Dec 08, 2025
18648288 METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF LEE, ANDREW ELDRIDGE 3684 §101§102§103 Final Rejection Pending Apr 26, 2024
17409589 METHODS OF TREATING CANCER BENAVIDES, JENNIFER ANN 1675 §103§112 Non-Final OA 23d Pending Aug 23, 2021

Managing Citius Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month